Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019
Q2 FY21 results · Jul–Sep 2020
Jubilant Pharmova reported revenue from operations of ₹2,374.89 crore (up 4.8% from Q2 FY20) and net profit of ₹224.12 crore (down 10.1% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,374.89 | 2,265.93 | +4.8% | 1,892.92 | +25.5% |
| Other income | 7.28 | 12.26 | −40.6% | 8.13 | −10.5% |
| Total income | 2,382.17 | 2,278.19 | +4.6% | 1,901.05 | +25.3% |
| Profit before tax | 313.67 | 292.23 | +7.3% | 122.10 | +156.9% |
| Net profit for the period | 224.12 | 249.39 | −10.1% | 88.01 | +154.7% |
| Attributable to shareholders of the company | 224.03 | 249.39 | −10.2% | 88.01 | +154.6% |
| EPS, basic (₹) | 14.06 | 15.66 | −10.2% | 5.53 | +154.2% |
| Net margin (%) | 9.4 | 11.0 | 4.6 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 760.75 | 757.54 | +0.4% | 753.95 | +0.9% |
| Other income | 12.89 | 79.08 | −83.7% | 8.98 | +43.5% |
| Total income | 773.64 | 836.62 | −7.5% | 762.93 | +1.4% |
| Profit before tax | 75.23 | 106.20 | −29.2% | 71.08 | +5.8% |
| Net profit for the period | 62.63 | 143.07 | −56.2% | 52.04 | +20.3% |
| EPS, basic (₹) | 3.93 | 8.98 | −56.2% | 3.27 | +20.2% |
| Net margin (%) | 8.2 | 18.9 | 6.9 |
Consolidated
- Filed with BSE
- 06 Nov 2020, 14:46 IST
- Board meeting
- 04 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Nov 2020, 14:46 IST
- Board meeting
- 04 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE